Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jasper Therapeutics, Inc. - Class A Common Stock (NQ:JSPR)

3.680 +0.660 (+21.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Jasper Therapeutics, Inc.
Via GlobeNewswire
Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Jasper Therapeutics, Inc.
Via GlobeNewswire
Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
From Jasper Therapeutics, Inc.
Via GlobeNewswire
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth. 
Via MarketBeat
Topics Retirement
Jasper Therapeutics, Inc. (NASDAQ: JSPR) Featured in Coverage of the Inaugural EF Hutton Global Conference
Via Investor Brand Network
Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
From Jasper Therapeutics, Inc.
Via GlobeNewswire
Accelerating R&D Activities in Breast Cancer Therapy Market Fueling Optimism for Development of Advanced Treatments
Palm Beach, FL – October 14, 2021 – FinancialNewsMedia.com News Commentary – The breast cancer drugs market, which has been steadily growing over the past few years, is projected to continue this trend... 
Via FinancialNewsMedia
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.